Ilorasertib hydrochloride
(Synonyms: ABT-348 hydrochloride) 目录号 : GC38519
A multi-kinase inhibitor
Cas No.:1847485-91-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Ilorasertib is a multi-kinase inhibitor.1 It inhibits Aurora C, VEGFR1, VEGFR2, FLT3, colony-stimulating factor 1 receptor (CSF1R), and Aurora B (IC50s = 1, 1, 2, 1, 3, and 7 nM, respectively). It also inhibits PDGFRα, PDGFRβ, c-Kit, VEGFR3, and Aurora A (IC50s = 11, 13, 20, 43, and 120 nM, respectively). Ilorasertib inhibits autophosphorylation of Aurora A, -B, and -C in HeLa cells with IC50 values of 189, 13, and 13 nM, respectively. It inhibits proliferation of a variety of cancer cells, including MV4-11 acute myeloid leukemia (AML), SUP-B15 acute lymphocytic leukemia (ALL), and H1299 non-small cell lung cancer (NSCLC) cells (IC50s = 0.3, 4, and 2 nM, respectively). It decreases histone H3 phosphorylation in blood-borne tumor cells in an engrafted mouse model of leukemia when administered at a dose of 25 mg/kg and reduces tumor growth in fibrosarcoma, pancreatic carcinoma, ALL, and multiple myeloma mouse xenograft models.
1.Glaser, K.B., Li, J., Marcotte, P.A., et al.Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase familiesJ. Pharmacol. Exp. Ther.343(3)617-627(2012)
| Cas No. | 1847485-91-9 | SDF | |
| 别名 | ABT-348 hydrochloride | ||
| Canonical SMILES | O=C(NC1=CC=CC(F)=C1)NC2=CC=C(C3=CSC4=C3C(N)=NC=C4C5=CN(CCO)N=C5)C=C2.[H]Cl | ||
| 分子式 | C25H22ClFN6O2S | 分子量 | 525 |
| 溶解度 | DMSO: 41.67 mg/mL (79.37 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9048 mL | 9.5238 mL | 19.0476 mL |
| 5 mM | 0.381 mL | 1.9048 mL | 3.8095 mL |
| 10 mM | 0.1905 mL | 0.9524 mL | 1.9048 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。